Journal of Cancer Research and Reports

Research Article

T Regulatory Cells: A Double-Edged Sword in HCC Diagnosis and Prognosis

Mohamed Elborei*

Pharmacology and Toxicology Department, Faculty of Pharmacy, MTI University, Egypt.

Keywords

Hepatocellular carcinoma, Tumour microenvironment, T Regulatory Cells.

Corresponding Author Information

Mohamed Elborei

Pharmacology and Toxicology Department, Faculty of Pharmacy, MTI University, Egypt, E-mail: Pharmacist900@gmail.com.

Received: July 03, 2025; **Accepted:** August 05, 2025; **Published:** August 18, 2025

Citation: Mohamed Elbore. T Regulatory Cells: A Double-Edged Sword in HCC Diagnosis and Prognosis. J Can Res Rep. 2025; 1(1):1-2.

Introduction

Hepatocellular carcinoma (HCC) stands among the deadliest cancers worldwide, and part of its resilience lies in its ability to manipulate the immune system. Within the tumour microenvironment (TME), regulatory T cells (Tregs) characterized by the markers CD4+CD25+FoxP3+ play a paradoxical role. While they are vital for maintaining immune balance under normal conditions, in the context of HCC, they suppress anti-tumour responses, helping the cancer evade immune detection. Tregs show significant potential as both diagnostic and prognostic markers. However, targeting them for therapy remains a complex endeavour. In this piece, I explore how a deeper understanding of Tregs could reshape the clinical management of HCC, while acknowledging the challenges posed by their dual roles

The Role of Treg Cells in HCC: Immunosuppression at the Core

Tregs compromise the body's anti-tumour defences by inhibiting cytotoxic T lymphocytes (especially CD8+ cells) and releasing immunosuppressive cytokines such as IL-10 and TGF-β. In patients with HCC, increased infiltration of Tregs within tumours has been associated with more advanced disease and poorer survival outcomes [1]. Their presence, marked by high FoxP3 expression, facilitates immune escape mechanisms that allow tumours to grow unchecked. This duality being protective in autoimmune diseases but harmful in cancer makes them a difficult yet intriguing target for therapy. I believe that a detailed understanding of Treg function is essential for leveraging their potential in HCC treatment

Tregs as Diagnostic Biomarkers: Unlocking Non-Invasive Detection

Tregs may serve as early indicators of HCC. Research shows that Treg levels in peripheral blood can help distinguish HCC patients from those suffering from chronic liver conditions [2]. Moreover, the identification of Treg-associated gene signatures and cytokines, like IL-10, might offer non-invasive tools for early diagnosis especially in high-risk groups such as individuals with hepatitis B or liver cirrhosis. While techniques like flow cytometry and immunohistochemistry remain standard for measuring Tregs, emerging liquid biopsy methods may pave the way for routine clinical use. I propose that incorporating Treg-based markers into regular screening protocols could significantly improve early HCC detection, though ensuring their specificity remains a key hurdle.

Prognostic Relevance: A Window into Patient Outcomes

Treg levels don't just assist in diagnosis they also offer valuable prognostic insight. High numbers of Tregs within the tumour are associated with reduced overall survival and disease-free survival [3]. Even more telling is the ratio of Tregs to CD8+ T cells: a high ratio strongly predicts poor outcomes [4]. Treg levels may also signal resistance to immunotherapies like checkpoint inhibitors,

adding another layer of complexity to treatment planning. I suggest that routinely assessing Treg levels alongside traditional markers like AFP could help stratify patients more effectively and tailor therapies although further research is needed to account for variations in HCC caused by different underlying liver diseases.

Therapeutic Potential and Limitations: Walking a Tightrope

There's growing interest in therapies that aim to reduce or modulate Treg activity to restore effective immune responses. Preclinical studies suggest that drugs like low-dose cyclophosphamide or anti-CD25 antibodies can suppress Tregs and enhance tumour immunity [5]. Combining such approaches with checkpoint inhibitors or localized treatments like TACE (trans arterial chemoembolization) may improve therapeutic outcomes. However, these strategies are not without risk broad Treg depletion could provoke autoimmune reactions, and the diverse nature of Treg subsets complicates selective targeting. I argue that future therapies should focus on modulating Tregs rather than eliminating them entirely, aiming for precision and minimizing side effects.

Looking Ahead: The Future of Treg Research in HCC

Emerging technologies, including single-cell RNA sequencing and multi-omics profiling, may soon allow researchers to identify distinct subtypes of Tregs with different roles in HCC. Machine learning could help integrate Treg data with clinical and genomic information, enabling more personalized and precise cancer care. For these advancements to reach the clinic, we need large, multi-centre trials that validate Treg-based biomarkers and therapies. I believe that continued investment in Treg research is essential to bridging the gap between lab-based discoveries and real-world applications in HCC management [6,7].

Conclusion

Treg cells present both opportunities and challenges in the fight against HCC. They have the potential to improve early diagnosis and predict patient outcomes, yet they also complicate treatment due to their immunosuppressive functions. If we can learn to navigate their dual nature harnessing their diagnostic and prognostic power while carefully modulating their activity, we may be able to shift the landscape of HCC care from reactive to proactive. The key lies in using our growing understanding of Treg biology to develop smarter, safer, and more effective interventions.

References

1. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25: 2586-2593.
2. Zhang CY, Liu S, Yang M. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World J Gastroenterol. 2022; 28: 3346-3358.
3. Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumour microenvironment: New mechanisms, potential therapeutic strategies and prospects. Mol Cancer. 2020; 19: 116.
4. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. Increased Regulatory T Cells Correlate with CD8 T-Cell Impairment and Poor Survival in Hepatocellular Carcinoma Patients. Gastroenterology. 2007; 132: 2328-2339.
5. Dwarakanath BS, Farooque A, Gupta S. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects. Cancer Rep. 2018; 1: e21105.
6. Zhang Q, He Y, Luo N, Patel SJ, Han Y, et al. Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell. 2019; 179: 829-845.
7. Li S, Lin Y, Gao X, Zeng D, Cen W, et al. Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance. Front Immunol. 2024; 15: 1517312.